Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:52:14.651Z.
Calculation as of: 2026-10-06T21:52:14.651Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23bdec7124bcf20b562f8235598f93689ea1cbdfcf2aa7384f68a4c8921eaa93
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$8.67B
EV/EBITDA Ratio
N/A
TTM Avg
48.39x
3Y Avg
48.39x
5Y Avg
48.39x
Market Cap
$8.92B
EV/EBITDA Ratio
142.09x
TTM Avg
219.04x
3Y Avg
94.19x
5Y Avg
94.19x
Market Cap
$8.93B
EV/EBITDA Ratio
29.89x
TTM Avg
147.75x
3Y Avg
144.67x
5Y Avg
144.67x
Market Cap
$8.38B
EV/EBITDA Ratio
7.27x
TTM Avg
74.89x
3Y Avg
49.56x
5Y Avg
49.56x
Market Cap
$9.21B
EV/EBITDA Ratio
30.68x
TTM Avg
23.19x
3Y Avg
21.87x
5Y Avg
21.39x
Market Cap
$7.99B
EV/EBITDA Ratio
60.46x
TTM Avg
53.51x
3Y Avg
69.46x
5Y Avg
69.46x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.72B | N/A | N/A | N/A | N/A |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | N/A | 48.39x | 48.39x | 48.39x |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.92B | 142.09x | 219.04x | 94.19x | 94.19x |
| Bruker Corporation (BRKRP)vs › | $8.93B | 29.89x | 147.75x | 144.67x | 144.67x |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 7.27x | 74.89x | 49.56x | 49.56x |
| Bruker Corporation (BRKR)vs › | $9.21B | 30.68x | 23.19x | 21.87x | 21.39x |
| Insulet Corp. (PODD)vs › | $9.33B | 15.69x | 28.49x | 45.32x | 85.61x |
| TG Therapeutics, Inc. (TGTX)vs › | $7.99B | 60.46x | 53.51x | 69.46x | 69.46x |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.81B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
